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Abstract
Objectives
The visceral adiposity index (VAI), an indirect marker of visceral adipose tissue, serves as a
model associated with cardiometabolic risk, but has limitations regarding the Asian popula-
tion. We sought to develop a new VAI (NVAI) for the Korean population and compare it to
VAI for prediction of atherosclerotic cardiovascular disease (ASCVD) risk and development
of major cardiovascular diseases (CVD) and stroke.
Methods
Patients (969) who underwent visceral fat area measurement were analyzed. After exclu-
sion, 539 patients (142 men, 397 women) were randomly divided into internal (n = 374) and
external validation (n = 165) data set. The NVAI was developed using univariate and multi-
variate logistic regression with backward selection of predictors. Receiver operating charac-
teristic (ROC) curve analysis and comparison of the area under the curve (AUC) verified the
better predictor of ASCVD risk score. Additionally, nationwide population-based cross-sec-
tional survey data (Korean National Health and Nutrition Examination Survey [KNHANES]
2008–2010, n = 29,235) was used to validate the NVAI’s ability to predict ASCVD risk and
major CVD and stroke.
Results
The NVAI better reflected visceral fat area in internal and external data sets, with AUCs of
0.911 (95% confidence interval [CI]: 0.882–0.940) and 0.879 (95% CI: 0.828–0.931),
respectively. NVAI better discriminated for ASCVD risk (AUC = 0.892, 95% CI: 0.846–
0.938) compared to VAI (0.559, 95% CI: 0.439–0.679). The NVAI also better predicted MI or
angina, and stroke with AUCs of 0.771 (95% CI: 0.752–0.789), and 0.812 (95% CI: 0.794–
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0.830), respectively, compared with waist circumference (WC), body mass index (BMI), TG
to HDL ratio, and VAI via KNHANES, in a statistically significant manner.
Conclusions
The NVAI has advantages as a predictor of visceral obesity and is significantly associated
with ASCVD risks and development of major CVD and stroke in the Korean population. The
NVAI could be a screening tool for improved risk estimation related to visceral obesity.
Introduction
It is well known that abdominal visceral fat is related to insulin resistance regardless of body
mass index (BMI). In most studies, abdominal visceral fat is a better determinant of cardiome-
tabolic risk factors such as hypertension, type 2 diabetes, and dyslipidemia than abdominal
subcutaneous fat [1–8]. Furthermore, abdominal visceral fat has a stronger association with a
risk of cardiovascular [3, 5, 8] and cerebrovascular disease compared with other anthropomet-
ric measures (e.g. BMI, total fat, and waist circumference [WC]) [9–11].
Computed tomography (CT) and magnetic resonance imaging (MRI) precisely and reliably
quantify individual differences in abdominal fat distribution and distinguish visceral adipose
tissue from subcutaneous adiposity, but both methods are expensive and CT has a high risk of
radiation exposure [12]. Thus, Amato et al. established the visceral adiposity index (VAI)
model that was based on a Caucasian population; this multivariate model includes non-inva-
sive, simple parameters (WC, BMI, serum triglycerides [TG], and high-density lipoprotein
[HDL] cholesterol levels) to incorporate functionality in deriving a measure of dysfunctional
adipose tissue that is not directly visceral adiposity [13]. VAI significantly correlates with meta-
bolic syndrome and cardiovascular risk [13]. However, there are conflicting data [14–17],
partly due to the study of different populations and ethnicity groups [17–21]. The application
of the VAI to non-Caucasian populations is limited, and there is little data regarding the
Korean population.
Our study sought to develop a new VAI (NVAI) applicable to the Korean population and
compare the efficacy of the NVAI for prediction of ASCVD risk and development of major
cardiovascular diseases (CVD) and stroke.
Methods
Study population
We analyzed 969 patients (262 men and 707 women) who voluntarily visited the Family medi-
cine obesity clinic at the Severance Hospital from March 2008-May 2017 and received an
abdominal CT scan for an obesity-related health check-up. Exclusion criteria were: a history of
hypertension, diabetes, dyslipidemia, or coronary artery occlusive disease (CAOD). Missing
data regarding metabolic parameters as well as foreigners were also excluded. After these
exclusions, 539 patients were included for final analysis. In order to validate the NVAI, the 539
patients were randomly divided into an internal dataset (n = 374 [69.4% of total patients, 100
men and 274 women]) and an external validation set (n = 165 [30.6% of total patients, 42 men
and 123 women]). This was a conventional statistical way to split the data according to a 7:3
proportion [22]. NVAI was developed using an internal data set and verified using an external
data set. Additionally, we used national representative population-based cross-sectional survey
Visceral adiposity index and cardiometabolic risk
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data (Korean National Health and Nutrition Examination Survey [KNHANES] 2008–2010) to
validate the predictive ability of the NVAI for the ASCVD risk and development of major
CVD and stroke. After exclusion, 6,259 patients (aged 40–79 years; 2,496 men and 3,763
women) were enrolled and analyzed with regard to age, sex, race, diabetes status, smoking sta-
tus, treated and untreated high blood pressure, systolic blood pressure, total serum cholesterol,
and serum HDL-cholesterol to obtain the ASCVD 10-year risk score (Fig 1). A total of 29,235
patients (13,328 men and 15,907 women) were used to verify the predictive ability of the
NVAI for major CVD and stroke (Fig 1). We retrospectively reviewed the medical records of
participants. The medical record data was recorded by the investigator in such a way that the
patients cannot be identified (i.e., by the investigator or others) either directly, or indirectly via
linkage codes assigned to the data. Therefore, the need for consent was waived and the study
was conducted in accordance with the Declaration of Helsinki and approved by the Institu-
tional Review Board of Gangnam Severance Hospital (IRB No: 3-2018-0054).
Clinical and anthropometric evaluation
All participants completed a uniform questionnaire detailing their medical history, medication
usage, smoking status, and alcohol consumption (S1 Appendix). Height was measured to the
closest 0.1 cm and the weight was measured to the closest 0.1 kg using an automatic height-
Fig 1. Flowchart for patient group selection. KNHANES, Korean National Health, and Nutrition Examination Survey; HTN, hypertension; DM, diabetes mellitus;
CAOD, coronary artery occlusive disease; MI, myocardial infarction; ASCVD, atherosclerotic cardiovascular disease.
https://doi.org/10.1371/journal.pone.0203787.g001
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weight scale (BSM 330, Biospace, Seoul, Korea). BMI was estimated based on weight (kg)
divided by height (m2). WC was measured at the umbilicus with the patient in the standing
position. The same person acquired all measurements of the anthropometric parameters
throughout the study in order to reduce variations. Blood pressure was measured using an
electronic manometer (BPBio320, Biospace) after more than 10 minutes of rest in a seated
position, and the mean blood pressure (MBP) was calculated as [1/3 (systolic blood pressure)
+ 2/3 (diastolic blood pressure)] based on an average of two measurements.
Abdominal fat areas were calculated by CT (Tomoscan 350; Philips, Mahwah, NJ, USA). As
described in detail previously [23], with the patient in a supine position, a 10-mm CT slice
scan was acquired at the L4 to L5 level to measure the total abdominal and visceral fat area.
The visceral fat area was quantified by delineating the intra-abdominal cavity at the internal
aspect of the abdominal and oblique muscle walls surrounding the cavity and the posterior
aspect of the vertebral body. The subcutaneous fat area was calculated by subtracting the vis-
ceral fat area from the total abdominal fat area. The coefficients of variation for inter- and
intra-observer reproducibility were 1.4% and 0.5%, respectively.
With regard to smoking habits, a cigarette smoker was defined as a person who currently
smokes and had smoked more than 100 cigarettes during their lifetime. The ingestion of alco-
hol was defined as more than two to three drinks per week.
Biochemical analysis
Blood samples were obtained from an antecubital vein of each patient after an 8-hour over-
night fast. Fasting serum glucose, total cholesterol, TG, and HDL-cholesterol were measured
with the ADVIA 1650 Clinical Chemistry System (Siemens Medical Solutions, Tarrytown, NY,
USA). Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equa-
tion if the serum TG level was below 400 mg/dL. Fasting insulin was determined with an elec-
trochemiluminescence immunoassay using an Elecsys 2010 instrument (Roche, Indianapolis,
IN, USA).
Definition of metabolic syndrome, visceral adiposity index, and ASCVD
risk score
Metabolic syndrome was defined as meeting three or more of the following criteria based on
the revised National Cholesterol Education Program Adult Treatment Panel III definition and
the Korean Society for the Study of Obesity [24]: (1) abdominal obesity (WC90 cm in men
or85 cm in women); (2) fasting TG of150 mg/dL; (3) low HDL-cholesterol (<40 mg/dL
in men or <50 mg/dL in women); (4) increased blood pressure (systolic blood pressure130
mmHg, diastolic blood pressure85 mmHg, or taking of anti-hypertensive medications); and
(5) impaired fasting glucose (fasting glucose100 mg/dL or use of insulin or hypoglycemic
medication), as described previously in detail [25].
Visceral obesity was defined as a person whose visceral fat area was more than 100 cm2, as
measured by CT [26].
VAI was defined based on WC, BMI, serum HDL-cholesterol, and TG levels, as described
by Amato et al [13].
Males : VAI ¼ ½WC=ð39:68 þ 1:88 BMIÞ  ðTG=1:03Þ  ð1:31=HDLÞ
Females : VAI ¼ ½WC=ð36:58 þ 1:89 BMIÞ  ðTG=0:81Þ  ð1:52=HDLÞ
A total of 374 patients (internal dataset) was used to build the NVAI. We considered vari-
ables significantly associated with the visceral fat area (>100 cm2) via univariate analysis. We
Visceral adiposity index and cardiometabolic risk
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checked multicollinearity of the variables and included age, BMI, WC, MBP, fasting plasma
glucose, insulin, TG, HDL-cholesterol, LDL-cholesterol, and current smoking and drinking
status to perform a logistic regression with backward (Wald) selection of predictors. We set
the criterion for p-values at 0.05 to select an entry or a removal. After performing seven steps
of logistic regression with backward selection of predictors, the final model of the NVAI was
composed of age, WC, MBP, TG, and HDL-cholesterol and is described below. The β value of
each variable is stated with the standard error below each equation.
Male : NVAI ¼ 1=½1þ expf  ð  21:858þ ð0:099 ageÞ þ ð0:10WCÞ
þð0:12MBPÞ þ ð0:006 TGÞ þ ð  0:077HDLÞÞg
b :   21:858 ð6:33Þ; age : 0:099 ð0:036Þ; WC : 0:10 ð0:041Þ; MBP : 0:122 ð0:042Þ;
TG : 0:006 ð0:003Þ; HDL :   0:077 ð0:039Þ
Female : NVAI ¼ 1=½1þ expf  ð  18:765þ ð0:058 ageÞ þ ð0:14WCÞ
þð0:057MBPÞ þ ð0:004 TGÞ þ ð  0:057HDLÞÞg
b :   18:765 ð2:95Þ; age : 0:058 ð0:015Þ; WC : 0:14 ð0:023Þ; MBP : 0:057 ð0:020Þ; TG
: 0:004 ð0:003Þ; HDL :   0:057 ð0:018Þ
The ASCVD risk score is defined as non-fatal myocardial infarction, coronary heart disease
death, or stroke by 2013 ACC/AHA guideline. This is pooled cohort equations for the predic-
tion of ASCVD 10-year risk among patients who have never experienced any of these events in
the past. We set cutoff value of 7.5%, which is guideline of starting moderate or high intensity
statin to reduce ASCVD risk in adults [27, 28].
Statistical analysis
Data are expressed as mean ± standard deviation (SD) or frequency (percentage). Variables
were tested for normality using the Kolmogorov-Smirnov test. Differences between groups
with univariate analysis were detected by independent sample t-test and Mann Whitney U-test
for continuous variables or a Chi-square test for categorical variables. Partial Pearson correla-
tion was conducted between VAI, NVAI, and clinical variables. Univariate and multivariate
logistic regression with backward (Wald) selection of predictors were used to build the NVAI.
Receiver operating characteristic (ROC) curve analysis was performed to determine the better
predictor of visceral fat area>100 cm2 by the area under the curve (AUC). Comparison of
AUCs was performed using the DeLong method. The ROC curve analysis and comparison of
AUCs were also used to compare the predictability of the ASCVD risk and development of
major CVD and stroke between the NVAI and other risk factors.
We utilized nomograms to verify the eligibility of the NVAI with external validation data
(using R package version 3.1.3). The Hosmer and Lemeshow goodness-of-fit test was used to
assess the acceptability of the predictive models, as it determined how well the nomogram was
calibrated, i.e., close approximation between the observed probability and the predicted proba-
bility demonstrated good calibration and confirmed the exportability of the NVAI. The stan-
dardized Pearson and deviance residual analysis were also used to assess the suitability of the
predictive model (S2 Appendix). The nomogram is intuitive, easily calculates the predictive
model of the visceral fat area and can be used in routine clinical practice (S3 Appendix).
Statistical analyses were performed with SPSS software (version 23.0; SPSS Inc., Chicago,
IL, USA) and R package (version 3.1.3). P-values <0.05 were considered statistically
significant.
Visceral adiposity index and cardiometabolic risk
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Results
The clinical characteristics of the patients are shown in Table 1. The total data set included 142
men and 397 women (mean age 36.0 ± 12.5 years). The internal data set was composed of 100
men and 274 women (mean age 36.4 ± 12.9 years), and the external validation data set
included 42 men and 123 women (mean age 35.1 ± 11.6 years).
S4 Appendix shows the clinical characteristics of the subgroup analysis for ASCVD 10-year
risk (internal data set and a subgroup of KNHANES) and major CVD and stroke for the full
data of KNHANES. The internal data set subgroup was composed of 25 men and 104 women
(mean age 50.4 ± 8.7 years). The mean systolic blood pressure, total cholesterol, and HDL-cho-
lesterol were 127.8 ± 17.8 mmHg, 196.4 ± 40.5 mg/dL, and 51.7 ± 11.0 mg/dL, respectively.
The external validation set from the KNHANES subgroup included 2,496 men and 3,763
women (mean age 53.9 ± 10.7 years) with a mean systolic blood pressure, total cholesterol, and
HDL-cholesterol of 117.0 ± 16.7 mmHg, 188.2 ± 27.1 mg/dL, and 52.3 ± 9.2 mg/dL, respec-
tively. The total patients from KNHANES included 13,328 men and 15,907 women (mean age
Table 1. Clinical characteristics of the study population.
Total (n = 539) Internal data set (n = 374) External validation (n = 165)
Factors Male (n = 142) Female (n = 397) Male (n = 100) Female (n = 274) Male (n = 42) Female (n = 123)
Age (years) 35.3 ± 13.1 36.2 ± 12.3 35.4 ± 13.1 36.7 ± 12.9 34.9 ± 13.3 35.1 ± 11.0
BMI (kg/m2) 31.2 ± 4.7 27.9 ± 5.0 31.6 ± 4.6 27.7 ± 4.9 30.0 ± 4.7 28.2 ± 5.2
WC (cm) 106.3 ± 15.6 92.2 ± 10.8 107.3 ± 17.0 91.8 ± 10.2 103.7 ± 11.5 93.0 ± 12.1
Visceral fat area (cm2) 135.0 ± 56.5 92.3 ± 44.4 137.5 ± 55.3 91.4 ± 41.0 129.0 ± 59.5 94.5 ± 51.2
Subcutaneous fat area (cm2) 304.1 ± 129.1 280.4 ± 129.6 311.4 ± 123.7 279.8 ± 129.0 286.8 ± 141.0 281.7 ± 131.4
Systolic BP (mmHg) 134.6 ± 15.7 121.2 ± 13.7 135.1 ± 16.8 121.3 ± 13.6 131.0 ± 12.1 121.1 ± 14.1
Diastolic BP (mmHg) 79.6 ± 10.7 72.0 ± 9.3 80.3 ± 11.0 72.0 ± 9.0 77.9 ± 9.7 72.0 ± 10.0
MBP (mmHg) 97.9 ± 11.6 88.5 ± 10.0 98.9 ± 12.3 88.5 ± 9,8 95.6 ± 9.7 88.4 ± 10.6
Fasting plasma glucose (mg/dL) 99.6 ± 18.1 93.0 ± 14.7 100.3 ± 20.0 91.8 ± 10.9 98.0 ± 12.3 95.8 ± 20.7
Insulin (μIU/mL) 19.3 ± 27.7 12.2 ± 14.1 20.7 ± 32.1 12.6 ± 15.9 16.1 ± 11.8 11.4 ± 8.8
Total cholesterol (mg/dL) 194.9 ± 38.1 190.0 ± 37.8 197.3 ± 36.8 189.2 ± 37.1 189.3 ± 41.1 191.9 ± 39.4
TG (mg/dL) 162.7 ± 92.1 109.3 ± 60.3 168.9 ± 103.0 111.3 ± 63.1 148.0 ± 56.8 104.8 ± 53.4
HDL-cholesterol (mg/dL) 42.5 ± 8.5 53.1 ± 12.1 42.4 ± 8.5 52.9 ± 11.7 42.8 ± 8.7 53.6 ± 12.9
LDL-cholesterol (mg/dL) 124.6 ± 35.9 117.3 ± 33.5 127.0 ± 34.8 116.5 ± 32.5 118.8 ± 38.0 119.0 ± 35.8
TG/HDL ratio 4.1 ± 2.7 2.3 ± 1.6 4.3 ± 3.1 2.3 ± 1.7 3.6 ± 1.7 2.2 ± 1.5
VAI 4.4 ± 4.0 3.5 ± 3.2 1.1 ± 0.12 1.0 ± 0.09 1.1 ± 0.05 1.0 ± 0.07
NVAI 0.73 ± 0.27 0.36 ± 0.31 0.77 ± 0.22 0.37 ± 0.31 0.62 ± 0.35 0.32 ± 0.31
Current smoker, N (%) 41 (28.9%) 21 (5.3%) 31 (31%) 18 (6.6%) 10 (23.8%) 3 (3.4%)
Alcohol drinker, N (%) 66 (46.5%) 51 (12.8%) 49 (49%) 32 (11.7%) 17 (40.5%) 19 (15.4%)
Values are presented as means ± standard deviation (SD) for continuous variables or number (percentage) for categorical variables.
VAI is a sex-specific mathematical index based on WC, BMI, TG, and HDL-cholesterol levels, indirectly expressing visceral adipose dysfunction associated with cardio
metabolic risk in a Caucasian Sicilian population.
The NVAI was derived from multivariate logistic regression analysis, based on age, WC, HDL-cholesterol levels, TG, and MBP, expressed by the following equation
Male: NVAI = 1/[1+exp{-(-21.858+(0.099×age) + (0.10×WC) + (0.12×MBP) + (0.006×TG)+(-0.077×HDL)}; β: -21.858 (6.33), age: 0.099 (0.036), WC: 0.10 (0.041), MBP:
0.122 (0.042), TG: 0.006 (0.003), HDL: -0.077 (0.039)
Female: NVAI = 1/[1+exp{-(-18.765 + (0.058×age) + (0.14×WC) + (0.057×MBP) + (0.004×TG) + (-0.057×HDL)}]; β: -18.765 (2.95), age: 0.058 (0.015), WC: 0.14 (0.023),
MBP: 0.057 (0.020), TG: 0.004 (0.003), HDL: -0.057 (0.018)
BMI, body mass index; WC, waist circumference; BP, blood pressure; MBP, mean blood pressure; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; VAI, visceral adiposity index; NVAI, new visceral adiposity index
https://doi.org/10.1371/journal.pone.0203787.t001
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39.0 ± 22.6 years) with a mean systolic blood pressure, total cholesterol, and HDL-cholesterol
of 115.5 ± 17.5 mmHg, 183.6 ± 36.5 mg/dL, and 48.3 ± 10.9 mg/dL, respectively.
As shown in Table 2, significant positive correlations were found between VAI and visceral
fat area, fasting glucose, fasting insulin, TG, LDL-cholesterol, number of metabolic syndrome
components, and ASCVD risk score, whereas significant negative correlation was found
between VAI and HDL-cholesterol levels after adjusting for age, sex, and BMI. A similar trend
was found between the NVAI and anthropometric and metabolic parameters. The NVAI was
positively associated with the visceral fat area, subcutaneous abdominal fat area, MBP, TG,
LDL-cholesterol, and number of metabolic syndrome components, whereas it was negatively
associated with HDL-cholesterol levels after adjusting for age, sex, and BMI.
All AUCs of NVAI and associated variables were compared and found to be larger than 0.7.
The predictive ability of the NVAI for visceral obesity displayed an AUC of 0.911 (SE: 0.015,
95% CI: 0.882–0.940) (Fig 2), which was significantly higher than WC, BMI, TG to HDL-cho-
lesterol ratio, and the VAI (AUC = 0.751, SE: 0.025, 95% CI: 0.703–0.800). The VAI did not
demonstrate a significant difference in prediction of visceral obesity compared with BMI or
WC (Table 3). External validation of the NVAI for visceral obesity displayed an AUC of 0.879
(SE: 0.026, 95% CI: 0.828–0.931), which was higher than WC, BMI, TG to HDL-cholesterol,
and the VAI (AUC = 0.720, SE: 0.040, 95% CI: 0.642–0.798), and calibration plots showed a
close approximation to the logistic calibration of each nomogram (Fig 3).
In order to determine the relative predictive ability of the NVAI for the ASCVD risk, ROC
curve and comparison were also performed. The AUC was 0.892 (SE: 0.023, 95% CI: 0.846–
0.938), which was significantly higher than WC, BMI, TG to HDL cholesterol ratio, and the
VAI (AUC of 0.559, SE: 0.061, 95% CI: 0.439–0.679) (Fig 4A). External validation by
KNHANES data was performed to validate these results, with an AUC of 0.858 (SE: 0.006, 95%
Table 2. Partial correlation between VAI, NVAI, and clinical variables.
VAIa NVAIa VAIb NVAIb
Factors r p-value r p-value r p-value r p-value
BMI 0.25 <0.001 0.72 <0.001 - - - -
WC (cm) 0.24 <0.001 0.65 <0.001 0.083 0.11 0.26 <0.001
Visceral fat area (cm2) 0.29 <0.001 0.57 <0.001 0.19 <0.001 0.31 <0.001
Subcutaneous fat area (cm2) 0.11 0.031 0.54 <0.001 -0.062 0.24 0.15 0.003
Visceral fat area (>100 cm2) 0.34 <0.001 0.64 <0.001 0.26 <0.001 0.50 <0.001
Systolic BP (mmHg) 0.12 0.018 0.50 <0.001 0.024 0.64 0.33 <0.001
Diastolic BP (mmHg) 0.10 0.057 0.46 <0.001 0.011 0.83 0.32 <0.001
MBP (mmHg) 0.12 0.023 0.52 <0.001 0.019 0.72 0.35 <0.001
Fasting plasma glucose (mg/dL) 0.20 <0.001 0.21 <0.001 0.14 0.009 0.014 0.79
Insulin, (μIU/mL) 0.22 <0.001 0.24 <0.001 0.16 0.002 0.06 0.30
TG (mg/dL) 0.93 <0.001 0.43 <0.001 0.92 <0.001 0.39 <0.001
HDL-cholesterol (mg/dL) -0.57 <0.001 -0.57 <0.001 -0.53 <0.001 -0.53 <0.001
LDL-cholesterol (mg/dL) 0.17 0.001 0.22 <0.001 0.13 0.016 0.13 0.016
Metabolic syndrome 0.55 <0.001 0.63 <0.001 0.51 <0.001 0.52 <0.001
a Adjusted for age and sex
b Adjusted for age, sex, and BMI
Metabolic syndrome was defined as fulfilling the modified National Cholesterol Education Program Adult Treatment Panel III and the Korean Society for the Study of
Obesity definitions.
VAI, visceral adiposity index; NVAI, new visceral adiposity index; BMI, body mass index; WC, waist circumference; BP, blood pressure, MBP, mean blood pressure; TG,
triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein
https://doi.org/10.1371/journal.pone.0203787.t002
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CI: 0.847–0.870), a statistically significant difference compared to other factors relevant to the
ASCVD risk (Fig 4B). When the predictive ability of the NVAI for a development of major
CVD and stroke was tested using the full external validation data of KNHANES, the NVAI
demonstrated statistically significant predictability for the presence of MI or angina with an
Fig 2. ROC curve for the prediction of visceral fat>100 cm2 using an internal data set. NVAI, new visceral
adiposity index; VAI, visceral adiposity index; WC, waist circumference; BMI, body mass index; TG, triglyceride;
HDL, high-density lipoprotein.
https://doi.org/10.1371/journal.pone.0203787.g002
Table 3. Post-hoc analysis of the AUC of NVAI for visceral obesity.
Index AUC (SE, 95% CI) Overall p-value Post-hoc p-value
NVAI 0.911 (0.015, 0.882–0.940) <0.001 Ref
VAI 0.751 (0.025, 0.703–0.800) <0.001 Ref
WC 0.832 (0.021, 0.791–0.873) <0.001 0.005 Ref
BMI 0.812 (0.022, 0.769–0.855) <0.001 0.04 0.08 Ref
TG/HDL ratio 0.789 (0.023, 0.744–0.834) <0.001 0.03 0.05 0.3
Post-hoc analyses were conducted using the DeLong method.
AUC, area under the curve; CI, confidence interval; NVAI, new visceral adiposity index; VAI, visceral adiposity index; WC, waist circumference; BMI, body mass index;
TG, triglyceride; HDL, high-density lipoprotein
https://doi.org/10.1371/journal.pone.0203787.t003
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AUC of 0.771 (SE: 0.009, 95% CI: 0.752–0.789) (Fig 4C). The presence of stroke was also statis-
tically well-predicted by NVAI, with an AUC of 0.812 (SE: 0.009, 95% CI: 0.794–0.830) com-
pared with WC, BMI, and the VAI (AUC of 0.633, SE: 0.017, 95% CI: 0.601–0.665) (Fig 4D).
Discussion
CVD remains the leading cause of death worldwide, despite improved outcomes for CVD
[29]. Recently, the declining trend in CVD has reached a plateau, necessitating an effort to gen-
erate more reliable data and powerful predictors to estimate the CVD burden and improve
prevention and management [30].
Conflicting results have been reported with respect to the relationship of obesity as mea-
sured by BMI and the development of CVD [31], and the metabolic consequences of obesity
vary according to the distribution of adipose tissue [3]. Indeed, visceral fat, not subcutaneous
fat, is important for cardiometabolic complications [32]. The mechanisms behind the differen-
tial impacts of visceral and subcutaneous fat tissue on cardiometabolic risk include differences
in adipocyte biology, inflammatory profiles, and connections to systemic circulation [32].
Although CT and MRI accurately distinguish between different types of body fat distribu-
tion, particularly visceral fat and subcutaneous fat tissue, these techniques are costly and not
routinely available [33]. Therefore, there is a need for simple alternatives that can identify vis-
ceral adiposity, such as WC, but WC does not distinguish between subcutaneous and visceral
fat mass [34]. Instead, the VAI was developed as an indirect marker of dysfunctional adipose
tissue and incorporates both the presence of visceral adipose tissue and functional factors,
which are indirectly expressed by high triglyceride/low HDL dyslipidemia [13]. In our study,
we developed the NVAI, which is composed of age, WC, MBP, TG, and HDL-cholesterol in
the Korean population. The NVAI significantly correlated with conventional cardiometabolic
Fig 3. External validation of the NVAI using a validation set. (A) Discrimination of the NVAI was good, with a predicted visceral fat of>100 cm2,
and values of 0.879 (SE: 0.026, 95% CI: 0.828–0.931) for the NVAI. (B) Calibrated plots demonstrate a close approximation to the logistic calibration
of each nomogram, indicating good agreement between predicted and observed outcomes when using the NVAI. Value of intercept was 0.098,
Value of slope was 0.834. WC, waist circumference; MBP, mean blood pressure; TG, triglyceride; HDL, high-density lipoprotein; ROC, receiver
operating characteristic.
https://doi.org/10.1371/journal.pone.0203787.g003
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Fig 4. ROC curve and AUC comparison of the NVAI for ASCVD risk and CVD. (A) ROC curve for the prediction of the ASCVD risk using internal
data set. (B) External validation for the prediction of the ASCVD risk using a subgroup of KNHANES IV-V. (C, D) ROC curve for predicting the
presence of MI, angina, and stroke using the full data of KNHANES IV-V. Post-hoc analyses were conducted using the DeLong method. The cutoff
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risk factors, and the AUC of NVAI for prediction of visceral obesity were significantly higher
than those of the VAI. Next, we illustrated the usefulness of NVAI as a predictor of the
ASCVD risk using an internal data set and nationwide population-based survey data
(KNHANES). When we compared VAI and VAI components with NVAI regarding predic-
tion of the ASCVD risk, the NVAI showed statistically significant prediction of the ASCVD
risk in both the internal data set and KNHANES subgroup without hypertension, diabetes,
dyslipidemia, and CAOD. In addition, NVAI had a better predictive value for major CVD and
stroke with the full KNHANES population data.
The VAI and NVAI were generated by multivariate logistic regression, which was based on
the same variables (WC, TG, and HDL-cholesterol) associated with abdominal visceral adipos-
ity. However, NVAI additionally included age and MBP, while the VAI was determined from
BMI. The exact reason for this difference is unknown, but ethnicity is considered the differ-
ence between the VAI (Caucasian population) and NVAI (Korean population). According to
several studies, Asian populations tend to accumulate more visceral fat tissue at lower BMI
and have a greater risk of metabolic complications and obesity-related CVD [3]. Therefore,
just as BMI can incorrectly label muscular Asian people as overweight or obese, BMI can also
erroneously categorize people with unhealthy amounts of fat as normal.
In our study, age was selected as an influential variable for visceral obesity. Cardiometabolic
disease not only increases with age, but aging is also associated with the accumulation of vis-
ceral fat; this increase nearly quadruples between the ages of 25 and 65 years [35]. In addition,
blood pressure was selected as a component of NVAI as well. There are several mechanisms
postulated to explain the association of hypertension and obesity [36]. Hyperinsulinemia due
to free fatty acid production from visceral adipose tissue could promote insulin resistance in
the liver and skeletal muscle [37, 38], and hyperinsulinemia increases sympathetic activity and
sodium tubular reabsorption [39]. Another assumption is that the compressive effect of vis-
ceral fat accumulation activates the renin angiotensin system, which increases sodium reab-
sorption, causing or exacerbating hypertension [40]. More longitudinal research is needed to
determine the differences in the VAI indices according to race and ethnicity and how the dif-
ferences affect ASCVD.
Our study has several limitations. First, this study was cross-sectional and limited in its abil-
ity to conclude causality. Second, ectopic fat is not measured, which may affect the relationship
between the NVAI and ASCVD risk. Third, we could not calculate sample sizes initially; how-
ever, we divided enrolled patients into internal and external sets in a 7:3 proportion and we
also used KNHANES data to verify the usefulness of NVAI. Fourth, this study was performed
using a sample enriched for obesity from a single health-care center and is limited for general-
ized applications. Future longitudinal studies with larger data sets are needed to support our
predictive model. Finally, the number of patients available for developing the NVAI is small,
making it difficult to generalize and apply results to an entire population. However, NVAI was
validated using nationally representative data to clarify the effects of NVAI on the ASCVD risk
and development of major CVD and stroke.
In conclusion, we developed a reliable indicator for better prediction of visceral obesity
than previous surrogate markers such as BMI, WC, and VAI in the Korean population. The
NVAI has advantages as a predictor of visceral obesity itself and is significantly associated with
value of the ASCVD 10-year risk score:7.5%. ROC, receiver operating characteristic; ASCVD, atherosclerotic cardiovascular disease; NVAI, new
visceral adiposity index; VAI, visceral adiposity index; WC, waist circumference; BMI, body mass index; TG, triglyceride; HDL, high-density
lipoprotein; AUC, area under the curve; CI, confidence interval; KNHANES, Korean National Health and Nutrition Examination Survey; MI,
myocardial infarction.
https://doi.org/10.1371/journal.pone.0203787.g004
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the ASCVD risk and development of major CVD and stroke. In this regard, the NVAI could
be used as a screening tool for improved risk estimation of major CVD or stroke.
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